Gastro-oesophageal reflux disease in type 2 diabetics: symptom load and pathophysiologic aspects - a retro-pro study by Regina Promberger et al.
Promberger et al. BMC Gastroenterology 2013, 13:132
http://www.biomedcentral.com/1471-230X/13/132RESEARCH ARTICLE Open AccessGastro-oesophageal reflux disease in type 2
diabetics: symptom load and pathophysiologic
aspects - a retro-pro study
Regina Promberger1, Johannes Lenglinger1, Otto Riedl2,3, Gernot Seebacher2, Wolf Hans Eilenberg1, Johannes Ott4,
Franz Martin Riegler1, Michael Gadenstätter2ˆ and Christoph Neumayer5*Abstract
Background: Information about gastro-oesophageal reflux disease (GERD) in patients with Diabetes mellitus type 2
(T2D) is scarce, although the incidence of both disorders is increasing.
We aimed to determine GERD symptoms and their underlying pathophysiologic characteristics in T2D patients.
Methods: This “retro-pro” study compared 65 T2D patients to a control group of 130 age- and sex-matched
non-diabetics. GERD was confirmed by gastroscopy, manometry, pH-metry and barium swallow.
Results: In patients with T2D compared to controls, dysphagia (32.3% vs. 13.1%; p = 0.001) and globus sensation
(27.7% vs. 13.8%; p = 0.021) were found more frequently, whereas heartburn (76.9% vs. 88.5%; p = 0.046) and
regurgitation (47.7% vs. 72.3%; p = 0.001) were predominant in non-diabetics. Despite higher body mass indices
(31.1 ± 5.2 vs. 27.7 ± 3.7 kg/m2; p < 0.001), hiatal hernia was less frequent in T2D patients compared to controls
(60.0% vs. 90.8%, p < 0.001). Lower oesophageal sphincter (LES) pressure was higher in patients with T2D (median
10.0 vs. 7.2 mmHg, p = 0.016). DeMeester scores did not differ between the groups. Helicobacter pylori infections
were more common in T2D patients (26.2% vs. 7.7%, p = 0.001). Barrett metaplasia (21.5% vs. 17.7%), as well as
low- (10.8% vs. 3.8%) and high-grade dysplasia (1.5% vs. 0%) were predominant in T2D patients.
Conclusions: T2D patients exhibit different GERD symptoms, higher LES pressures and a decreased prevalence of
hiatal hernia than non-diabetics, which may be related to worse oesophageal motility and, thus, a more functional
rather than anatomical cause of GERD. Low-grade dysplasia was more than twice as high in T2D than in
non-diabetics patients.
Trial registration: Ethics committee of the Medical University of Vienna, IRB number 720/2011.
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Gastro-oesophageal reflux disease (GERD) is one of the
most common disorders of the upper gastrointestinal tract
in developed countries. Up to 40% of the adult population
suffers from reflux symptoms [1]. At the same time, dia-
betes mellitus (DM), especially DM type 2 (T2D), which
accounts for up to 95% of diabetes cases, is dramatically* Correspondence: christoph.neumayer@meduniwien.ac.at
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distribution, and reproduction in any mediumincreasing worldwide. In 2010, 284.8 million people were
affected. It has been estimated that that number will rise
to 438.7 million diabetic adults in the year 2030 [2]. Thus,
both disorders are of increasing medical and socioeco-
nomic interest.
T2D has been described as a possible risk factor for the
development of GERD [3-6]. More recently, it has been
suggested that the metabolic syndrome defined by visceral
fat accumulation, dyslipidaemia, hypertension, and hyper-
glycaemia correlates with the occurrence of GERD [7]. As
recently reviewed, several pathophysiologic factors may
explain this finding: (i) hyperglycaemia causes increased
gastric H+ secretion, higher levels of bile acids, andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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gastric emptying, increased rates of transient lower
oesophageal sphincter (LES) relaxations, and decreased
LES pressure has been reported during hyperglycaemia in
patients with T2D; and, (iii) hiatal hernia and increased
obesity rates may also contribute to the development of
GERD in these patients [8].
However, many of the reviewed studies did not discrim-
inate between GERD-specific symptoms and general upper
gastrointestinal symptoms, which are frequently found in
diabetics [8]. Moreover, most studies were based on GERD
questionnaires and did not determine GERD using stand-
ard pH-metry and manometry [3-5,9,10]. To date, no study
exists about GERD and GERD-specific symptoms in pa-
tients with T2D that has included upper gastrointestinal
endoscopy, barium oesophagogram, manometry, and 24-
hour oesophageal pH-monitoring concurrently.
The aim of this study was to investigate GERD-specific
symptoms and reflux parameters in patients with T2D
using these standard diagnostic tools. Second, the results
were compared to non-diabetic GERD-patients in order
to explore possible diabetes-related differences. Special
emphasis was placed on extra-oesophageal GERD symp-
toms that have not been described for diabetics thus far.
Methods
Patient selection and assessment of symptom load
All patients referred to the motility laboratories of our
institutions for symptoms suggestive of GERD between
January 2007 and January 2009 were considered eligible
for this “retro-pro” case control study [11]. Exclusion
criteria were a body mass index (BMI) >35 kg/m2, type 1
(juvenile) diabetes, oesophageal motility disorders other
than ineffective oesophageal motility, and a history of
oesophageal or gastric surgery. The study group con-
sisted of patients with T2D and GERD-related symp-
toms. The diagnosis of T2D was based on the criteria
established by the American Diabetes Association [12].
Of a total of 588 patients, a control group of 130 non-
diabetic GERD patients (22.1%) was selected using age
and sex as matching criteria. A detailed history was
taken from all patients and they were asked to answer a
standardized questionnaire about upper gastrointestinal
symptoms before oesophageal function tests. Patients
were questioned regarding the presence of upper gas-
trointestinal symptoms, namely heartburn, epigastric
pain, regurgitation, respiratory symptoms, odynophagia,
globus sensation, dysphagia, flatulence, chronic cough,
hoarseness, bronchitis, and bronchial asthma. Bron-
chitis and bronchial asthma were only accepted as co-
morbidities if a specialist in respiratory medicine had
diagnosed them. All patients’ medication was also
assessed, with a focus on proton-pump inhibitors, pro-
kinetics, and anti-depressants.Data were prospectively gathered by a research assistant
and entered in a database. The study was approved by the
ethics committee of the Medical University of Vienna
(IRB number: 720/2011). The study was carried out in ac-
cordance with the “Good Scientific Practice” Standards of
the Medical University of Vienna, which are based on the
ethical standards of the Helsinki Declaration of 1975.
Written informed consent was obtained from all study
participants.
Oesophageal testing
All patients underwent upper gastrointestinal endoscopy,
stationary oesophageal manometry, barium oesopha-
gogram, and 24-hour oesophageal pH-monitoring.
Thereby, GERD was confirmed for all patients of both
the T2D and the control group. Upper gastrointestinal
endoscopy was routinely performed with sedation on a
Fujinon Video Endoscope System (Fujifilm Holdings
Corporation, Tokyo, Japan). Esophagitis was graded
using the Savary and Miller classification system [13]. A
hiatal hernia was diagnosed when the difference be-
tween the position of the crural impression and the
commencement of gastric-type folds was 2 cm or more.
The size of the hiatal hernia was noted. Standardized bi-
opsies were obtained from the oesophagus, the squamo-
columnar junction, and the gastric antrum. Visible
tongues or circular segments of columnar epithelium were
biopsied. A diagnosis of intestinal metaplasia (Barrett’s
oesophagus) was made if the presence of well-defined gob-
let cells within columnar epithelium was confirmed by a
pathologist who specialized in gastrointestinal disorders
[14]. Laryngeal lesions, including inflammation, edema,
leukoplakia, and ulcerations were also diagnosed or ruled
out, either in the course of upper gastrointestinal endos-
copy and/or laryngoscopy. An oto-laryngologist saw these
patients and confirmed the lesions.
All patients underwent standard, stationary, pull-
through oesophageal manometry using the Sandhill
EFT Impedance Manometry System ® (Sandhill Scien-
tific, Colorado, USA) with Bioview Software ® (Sandhill
Scientific, Colorado, USA). LES resting pressure and
swallow-induced relaxation was measured immediately
distal to the respiratory inversion point. LES was consid-
ered mechanically defective if the mean end-expiratory
pressure was below 8 mm Hg and/or a total LES length <
2 cm or an abdominal length < 1 cm was encountered
[15,16]. Oesophageal body motility was investigated with
ten water swallows of 5 ml at 30-second intervals. Propa-
gation and amplitudes of swallow-induced contractions
were recorded in the proximal, middle, and distal third of
the oesophageal body. A contraction wave was considered
to be ineffective if one or more of the following criteria ap-
plied: 1) amplitude in the distal oesophagus below
30 mmHg; 2) simultaneous propagation (> 20 mm/sec); or
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amplitudes < 15 mmHg). Impaired oesophageal motility
was diagnosed if more than 20% of oesophageal contrac-
tion waves fulfilled these criteria [17].
Twenty-four-hour oesophageal pH-monitoring was
performed using the Sandhill GER Impedance pH Metry ®
device (Sandhill Scientific, Colorado, USA) as described
previously [18]. In short, a single-use catheter fitted with
an antimony electrode was passed transnasally and posi-
tioned 5 cm proximal to the upper border of the LES. A
calibration of buffer solutions of pH 1 and pH 7 was
performed prior to each study. Endoluminal pH was
recorded for 20–24 hours at a frequency of 0.25 Hz, and
data were stored in a portable data logger. Patients were
instructed to follow their routine activities and to consume
their usual diet. The patients recorded meal periods and
times spent in recumbent positions. Sampled data were
transferred to a computer for analysis using DeMeester’s
composite score as the main variable. A score of more
than 14.7 indicated increased acid reflux. All medications
that could possibly interfere with oesophageal motor func-
tion (i.e., metoclopramide, cisapride, nitrates, beta-
agonists, and calcium-channel blocking agents) or gastric
acid secretion were discontinued at least seven days before
the studies. The use of sucralfate was permitted until one
day before reflux monitoring.
In addition, barium swallows, i.e., double-contrast
oesophagographies, were performed in all patients
through biphasic examination with upright air-contrast
and prone single-contrast views of the oesophagus. The
occurrence of spontaneous gastro-oesophageal reflux
was assessed, and the presence and size of hiatal hernias
were recorded.
Statistical analysis
Values are expressed as mean ± standard deviation (SD),
or median and interquartile range [IQR], if appropriate.
Concerning general patient characteristics, the chi-square
test and, if appropriate, Fisher’s exact test, were used to
compare proportions between groups. To compare differ-
ences, t-tests and u-tests were used. To compare propor-
tions and differences in outcome parameters between the
groups, univariate logistic regression models were used.
For these, p-values of the likelihood ratio tests, odds ratios
(OR) and 95% confidence intervals (95% CI) are provided.
Correlations were tested using Spearman rank correla-
tions. P values <0.05 were considered statistically sig-
nificant. The software SPSS 17.0 (SPSS Inc, Chicago,
1993–2007) was used for all statistical analyses.
Results
Patient characteristics
One-hundred-thirty non-diabetic GERD-patients were
enrolled in the study as a control-group. General patientcharacteristics are summarized in Table 1. BMI levels
were significantly higher in diabetic patients. When fo-
cusing on laboratory parameters, total cholesterol levels
were higher in the control group, whereas HbA1c and
triglyceride levels were higher in patients with T2D.
No differences were found between diabetics and non-
diabetics concerning the use of proton pump inhibitors
and pro-kinetics (59/65 [90.8%] vs. 118/130 [90.8%], p >
0.05; and 4/65 [6.2%] vs. 10/130 [7.7%], p > 0.05, respect-
ively). Anti-depressants were used more frequently in dia-
betics than in non-diabetics (14/65 [21.5%] vs. 7/130
[5.4%], p = 0.001, respectively).
When focusing on the characteristics of patients with
T2D only, 56 subjects had T2D for a median duration of
5.0 years (IQR 3.0-10.0 years; 29 women, 36 men). Neither
the duration of T2D, nor the duration of GERD correlated
with HbA1c levels (r = 0.254, p = 0.061 and r = −0.063, p =
0.617; respectively).
All diabetic subjects were treated dietetically. In
addition, 49 patients (75.4%) used hypoglycaemic agents,
such as metformin (40/65, 61.5%), gliclacid (6/65, 9.2%),
glibenclamid (2/65, 3.1%), and acarbose (1/65, 1.5%).
Twelve patients (18.5%) were insulin-dependent. The
co-morbidities of T2D patients comprised arterial hyper-
tension in 58.5% (38/65), peripheral neuropathy in 32.3%
(21/65), diabetic retinopathy in 13.8% (9/65), peripheral
arterial disease in 12.3% (8/65), and diabetic nephropa-
thy in 6.2% (4/65).
GERD-related symptoms
Table 2 provides data about GERD-related symptoms. In
short, patients with T2D reported dysphagia and globus
sensation more frequently, whereas heartburn, regurgita-
tion, and flatulence were predominant in non-diabetics.
The prevalence of respiratory symptoms did not differ
between both groups. When comparing the sum of
GERD symptoms between patients with and without
T2D, there was no essential difference (median 3, IQR
2–5 vs. median 4, IQR 3–5, respectively; p = 0.210). Like-
wise, diabetic patients with neuropathia and those with-
out did not differ concerning the sum of GERD
symptoms (median 3, IQR 2–4, vs. median 3, IQR 2–5,
respectively; p = 0.411). The duration of diabetes had no
impact on GERD symptoms either.
Laryngeal findings and oesophageal testing
Laryngeal lesions, including inflammation, oedema,
leukoplakia, and ulcerations were observed more fre-
quently in patients with T2D (16.9% vs. 7.0% in non-
diabetics, p = 0.032).
Results of oesophageal testing are given in Table 3.
When focusing on findings with differences between dia-
betic and non-diabetic patients only, upper GI endos-
copy revealed a hiatal hernia in 60.0% of patients with
Table 1 Comparison of general patient characteristics and laboratory parameters between GERD patients with and
without T2D
T2D GERD patients Non-diabetic GERD patients p
Patients (n) 65 130 —
Females (n [%]) 29 [44.6%] 58 [44.6%] n.s.*
Age (years, mean ± SD) 58.6 ± 9.2 58.5 ± 8.8 n.s.**
BMI (kg/m2, mean ± SD) 31.1 ± 5.2 27.7 ± 3.7 <0.001**
Smoking (n [%]) 18 [27.7%] 12 [10.1%] 0.002*
Duration of GERD symptoms (years, median [IQR]) 5.0 [3.0;10.0] 5.0 [2.0;11.0] n.s.***
HbA1c (%) 7.2 ± 1.1 5.3 ± 0.9 <0.001**
Total cholesterol (mg/d, mean ± SD) 204.2 ± 44.9 217.3 ± 38.0 0.013***
LDL* (mg/dl, mean ± SD) 126.6 ± 32.6 134.8 ± 36.9 n.s.***
HDL# (mg/dl, mean ± SD) 56.3 ± 16.0 60.2 ± 18.3 n.s.***
Triglycerides (mg/dl, mean ± SD) 183.0 ± 118.9 128.8 ± 66.4 <0.001***
Blood urea nitrogen (mg/dl, mean ± SD) 15.1 ± 4.9 13.7 ± 4.5 n.s.***
Creatinine (mg/dl, mean ± SD) 1.0 ± 0.2 0.9 ± 0.1 n.s.***
n number, SD Standard deviation, IQR Interquartile range, BMI Body mass index, n.s. Not significant; * chi-square test, ** t-test, *** u-test, p p-value.
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The sizes of hiatal hernias did not differ significantly be-
tween the groups (median 4 cm [IQR 3–5] for patients
with T2D vs. median 5 cm [IQR 4–7] for non-diabetics,
p = 0.060). An analysis of barium esophagograms re-
vealed hiatal hernias more frequently in non-diabetics.
Helicobacter pylori infections were more common in pa-
tients with T2D. Manometry revealed a significantly
higher median pressure of LES for diabetics.
HbA1c levels in patients with T2D did not correlate
with LES pressure, relaxation time, or peristalsis (r <0.30,






Heartburn 50 (76.9) 1
Epigastric pain 40 (61.5)
Regurgitation 31 (47.7)
Respiratory symptoms 40 (61.5)
Odynophagia 6 (9.2)
Globus sensation 18 (27.7)
Dysphagia 21 (32.3)
Flatulence 13 (20.0)
Chronic cough 28 (43.1)
Hoarseness 17 (26.2)
Bronchitis 10 (15.4)
Asthma bronchiale 9 (13.8)
n.s. not significant, p p-value.
Data are provided as n(%), multiple citations possible; all parameters were tested uDiabetes treatment-specific analyses
Symptoms, endoscopic, pH, and manometric parameters
in patients with T2D were also analyzed according to the
diabetes-specific therapy the patients were receiving.
There were no differences in all parameters between those
patients with dietary restrictions only (n = 10), those
with dietary restrictions and oral hypoglycaemic agents
(n = 43), and those who were also insulin-dependent (n =
12), apart from epigastric pain. This symptom was
reported less frequently in patients on oral medication
(51.2%) than in patients with dietary restrictions only (80%)







15 (88.5) 0.47 (0.21;0.99) 0.046
85 (65.4) 0.85 (0.46;1.57) n.s.
94 (72.3) 0.36 (0.20;0.67) 0.001
82 (63.1) 0.94 (0.51;1.73) n.s.
9 (6.9) 1.37 (0.47;4.02) n.s.
18 (13.8) 2.38 (1.14;4.80) 0.021
17 (13.1) 3.40 (0.90;12.79) 0.001
59 (45.4) 0.30 (0.15;0.61) 0.001
59 (45.4) 0.91 (0.50;1.66) n.s.
32 (24.6) 1.08 (0.55;20.14) n.s.
22 (16.9) 0.89 (0.39;2.02) n.s.
28 (21.5) 0.59 (0.26;1.33) n.s.
sing univariate logistic regression models.
Table 3 Results of oesophageal testing
T2D GERD patients Non-diabetic GERD patients OR (95% CI) p
n = 65 n = 130
Upper GI endoscopy
Hiatal hernia (n [%]) 39 [60.0] 118 [90.8] 0.49 (0.23;0.98) <0.001
Oesophagitis (n [%]) 30 [46.2] 43 [33.1] 1.86 (1.01;3.43) n.s.
Barrett metaplasia (n [%]) 11 [16.9] 35 [26.9] 0.58 (0.27;123) n.s.
Histology
Esophagitis (n [%]) 38 [58.5] 73 [56.2] 1.32 (0.73;2.42) n.s.
Barrett metaplasia (n [%]) 14 [21.5] 23 [17.7] 1.42 (0.67;3.02) n.s.
Low-grade dysplasia (n [%]) 7 [10.8] 5 [3.8] 3.80 (1.07;13.51) n.s.
High-grade dysplasia (n [%]) 1 [1.5] 0 [0] 3.28*e9 (0;inf) n.s.
Helicobacter pylori (n [%]) 17 [26.2] 10 [7.7] 4.72 (1.97;11.32) 0.001
Manometry
LES pressure (mm Hg, median [IQR]) 10.0 [6.1;15.0] # 7.2 [3.7;11.7] 1.06 (1.01;1.12) 0.016
Absent or decreased peristalsis (n [%]) 16 [27.6] # 23 [17.8] + 1.76 (0.85;3.65) n.s.
Twenty-four-hour oesophageal pH-monitoring
DeMeester score (median [IQR]) 24.6 [12.1;45.2] 29.7 [21.0;44.6] 0.99 (0.79;1.01) n.s.
Total relax. time (%, median [IQR]) 6.7 [4.0;11.5] 6.9 [4.6;12.5] 0.99 (0.67;1.47) n.s.
Upright relax. time (%, median [IQR]) 7.2 [4.1;13.2] 8.3 [4.7;14.0] 0.99 (0.96;1.03) n.s.
Lying relax. time (%, median [IQR]) 3.1 [0.0;12.8] 3.4 [0.6;8.6] 1.01 (0.97;1.04) n.s.
Barium esophagogram
Hiatal hernia (n [%]) 32 [49.2] 92 [70.8] 0.52 (0.28;0.96) 0.035
Reflux (n [%]) 28 [43.1] 68 [52.3] 0.81 (0.44;1.42) n.s.
n.s. not significant; # n = 58 (seven patients did not tolerate manometry), + n = 129 (one patient did not tolerate manometry), p p-value; all parameters were tested
using univariate logistic regression models.
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Diabetes is a major health problem, as it is an important
contributor to various other diseases and its incidence still
continues to rise. Despite the fact that its role as a risk fac-
tor for GERD has been demonstrated and that GERD itself
is of high clinical relevance, little light has been shed on
the connection between the two diseases [3,4,6]. For the
first time, the present study characterizes GERD patients
concurrently affected by T2D using well-established diag-
nostic methods for oesophageal testing.
The individual symptom load differs between diabetics
and non-diabetics [19]. In our study, dysphagia and globus
sensation were found significantly more frequently in
GERD patients with T2D. In the course of GERD, dyspha-
gia may be caused by decreased oesophageal motility or by
peptic oesophageal stricture due to acid reflux [20,21]. In
our study population, impaired peristalsis, as assessed by
manometry, was somewhat more frequent among patients
with T2D. Moreover, dysphagia has been shown to be re-
lated to the presence of high LES pressure in patients with
a hypertensive LES [22,23], which is also true for our
investigation.
Globus sensation has been reported to be a common
functional symptom due to inflammation of the throatcaused by GERD [24,25]. In our study, however, there
was no significant difference in DeMeester scores be-
tween the two groups. Diabetics used antidepressants
more frequently than non-diabetics. Psychological im-
pairment has been discussed as another possible factor
contributing to globus sensation [26]. The approximately
two-fold higher prevalence of laryngeal lesions in pa-
tients with T2D may also contribute to the increased
prevalence of globus sensation. The exact etiology of
globus sensation, however, remains incompletely under-
stood [27,28].
Epigastric pain and heartburn are known to be the most
frequent GERD-associated symptoms, occurring in up to
90% of patients with proven T2D [29]. Similar results have
been found in the present investigation. The higher preva-
lence of heartburn, defined as “hypersensitivity” to acid re-
flux in the non-diabetes group, may be explained, at least
partly, by diabetic neuropathy [4,8,30]. Moreover, the
higher rates of hiatal hernia in the non-diabetes group in
our study may have also contributed to the higher heart-
burn rate [31]. However, epigastric pain and heartburn are
not necessarily associated with GERD. Studies that deal
with symptoms only, without oesophageal testing, cannot
verify the actual presence of GERD [3-5,9,10]. Thus, a
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our findings is not valid.
Regurgitation, a major problem for many reflux pa-
tients, is predominant in non-diabetics and within the
range described for this population [8]. Increased rates
of hiatal hernia in the non-diabetes group may have had
an impact on this finding [31]. For patients with T2D,
however, the regurgitation rate of about 48% was much
higher in our study compared to 16% in a previous series
of type 2 diabetics [32]. Impaired peristalsis was found
more frequently in patients with T2D, which may be an-
other explaination for our findings.
Microaspiration of the gastro-oesophageal refluate and
subsequent airway inflammation, are the major mecha-
nisms that cause respiratory symptoms in GERD patients
[33-35]. Although the overall prevalence of respiratory
symptoms did not differ between T2D patients and non-
diabetics, it is noteworthy that laryngeal lesions, including
leukoplakia and ulcerations, were observed more fre-
quently in patients with T2D. Recently, epidemiologic evi-
dence has suggested that cancer incidence is associated
with DM, as well as certain diabetic risk factors, including
obesity [36-38]. Our goal, however, was not the long-term
observation of possible precancerous lesions. Nevertheless,
to the best of our knowledge, this is the first report de-
scribing extra-oesophageal reflux symptoms in diabetic
GERD patients.
Overall, the summed scores of GERD symptoms were
comparable in diabetics and non-diabetics in our study.
Similar results have been published earlier [19,39]. Like-
wise, GERD-specific quality of life was comparable in dia-
betic and non-diabetic patients although there were some
minor differences in health related quality of life [40]. All
in all, data on the prevalence of reflux symptoms vary
widely within T2D patients, ranging from 25.3% to 45.0%
[3,39]. In contrast to other studies, we did not screen for
GERD-related symptoms in diabetics since these symp-
toms were an inclusion criterion in our study.
Notably, the duration of T2D and the presence of
neuropathia had no major impact on GERD symptoms
in our investigation [41,42]. In the present series, this
was not the case. This is probably due to the fact that (i)
patients with T2D were under adequate glycaemic con-
trol, has already been pointed out earlier [3,9,43]. More-
over, (ii) the duration of GERD symptoms did not differ
compared to non-diabetics.
Hiatal hernia rates were relatively high in both groups.
Patients referred to our motility laboratories for GERD
diagnostics are usually those who still suffer from GERD-
related symptoms despite PPI intake. In general, hiatal
hernia is the major reason for persisting complaints [44].
This could possibly be some kind of ‘pre-selection’ of our
patients. However hiatal hernia rates were more frequent
in non-diabetics. This is a surprising result consideringthat higher BMI levels are known to be a risk factor for
the presence of hiatal hernia, and that higher BMI levels
were found in patients with T2D in our study [37,45].
Nevertheless, our results are in accordance with a previous
report demonstrating that, in morbidly obese patients, the
rate of hiatal hernia was inversely correlated with gly-
caemic control [46]. In diabetics, delayed gastric emptying
and decreased proximal retention of meals have been
reported [47]. Furthermore, an inverse correlation be-
tween proximal gastric volume and the formation of a
sliding hiatal hernia has been described [48]. Thus, altered
intragastric meal distribution in patients with T2D may
contribute to a lower prevalence of hiatal hernias in dia-
betic patients.
Higher BMI levels, as found in the T2D patients in
our study, are an established risk factor for the develop-
ment of GERD, and, thus, for esophagitis [49]. Notably,
histological rates of esophagitis and Barrett’s oesophagus,
as well as low-grade and high-grade dysplasia, were
somewhat higher in T2D patients compared to controls.
Although these results failed to reach statistical signifi-
cance, which is probably due to the relatively low num-
ber of patients, one has to emphasize the possible
clinical importance of such results, because, for example,
low-grade dysplasia was more than twice as high in dia-
betics than in non-diabetics (10.8% vs. 3.8%). It has
already been suggested that visceral fat, another contrib-
uting factor to T2D, was associated with Barrett’s
esophagitis, and with increased esophageal inflammation
and high-grade dysplasia in subjects with Barrett’s
esophagitis [50]. Moreover, since patients with T2D may
have a lower oesophageal sensitivity, as suggested by the
decreased heartburn rates, GERD and, in consequence,
precancerous lesions, might be diagnosed later than in
non-diabetics. However, the primary goal of our study
was not to prove the increased risk of T2D patients for
developing oesophageal adenocarcinoma, but to describe
T2D-related differences in the symptom load and the
pathophysiology of GERD. Consequently, surveillance
studies will be necessary in order to explore the cancer-
ous potential of T2D in GERD patients.
Our results showed significantly higher rates of
helicobacter pylori infection in patients with T2D. This is
in accordance with the published literature, as diabetics,
especially those with poor glycaemic control, are more
prone to infections [8,43]. Nevertheless, other studies
reported even higher percentages of helicobacter pylori in-
fection, with differences between diabetics and non-
diabetics of up to 80% versus 30%, respectively [51,52].
The discrepancy between these results and our findings
may be explained by the fact that many of our patients
had been pretreated by eradication therapy.
Hyperglycaemia decreases LES pressure in diabetics,
with up to 92% of patients having resting LES pressure
Promberger et al. BMC Gastroenterology 2013, 13:132 Page 7 of 8
http://www.biomedcentral.com/1471-230X/13/132between 0 and 8mmHG [30]. Consequently, lower LES
pressure predisposes to GERD [8]. In our investigation,
however, T2D patients had significantly higher LES pres-
sure levels compared to non-diabetics. Various studies
have dealt with LES pressure in diabetic subjects [30,53].
However, these data are only partly comparable to our
results, since all of these studies included diabetic pa-
tients without a history of GERD.
DeMeester scores were lower in T2D patients, al-
though not statistically significant. The higher preva-
lence of hiatal hernia in the non-diabetic group and the
significantly lower LES pressure may account for this
finding. In addition, high helicobacter pylori infection
rates could have ameliorated gastric secretion [8].
Notably, our data show no significant correlations be-
tween HbA1c levels and LES pressure, relaxation time,
or peristalsis. Gastrointestinal symptoms and complica-
tions do not always correlate with the duration of DM
and glycaemic control [43]. To date, no single risk factor
for GERD in T2D has been identified, as the aetiology of
GERD is multifactorial [43].
The limitation of our study is the retrosprective de-
sign, although all data were derived from a prospective
database. The relatively low number of patients might be
considered another drawback of the study. To the best
of our knowledge, however, this is the largest investiga-
tion on proven GERD in T2D.
Conclusion
T2D GERD patients (i) exhibit other types of symptoms
than do non-diabetics, especially dysphagia, globus sensa-
tion, and, at least to some extent, extra-oesophageal symp-
toms with higher rates of proven laryngeal lesions; (ii) are
infected with helicobacter pylori more frequently; and (iii)
show higher LES pressure levels; and (iv) lower rates of
hiatal hernia. The results may have some implications for
diagnostic and therapeutic strategies in diabetic GERD pa-
tients. Since the incidence of the most frequently encoun-
tered GERD symptom, namely heartburn, is lower in
patients with T2D, other signs and symptoms should lead
to the suspected diagnosis of GERD. Particularly with re-
gard to possibly higher rates of dysplasia and Barrett meta-
plasia in T2D GERD patients, the diagnostic work-up in
diabetic patients could be of the utmost importance.
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